Publication
Article
Pharmacy Times
Help Get Patients to Their LDL-C and A1C Goals: Welchol® (colesevelam HCl) and the ADDvantage Program™
Patients taking medications for high cholesterol and diabetes have a new resource for managing their drug therapy.
This product bulletin was brought to you by Daiichi Sankyo, Inc.
This product bulletin describes the efficacy and safety of Welchol, a bile acid sequestrant. Welchol is the first and only add-on to a statin and metformin that is approved by the FDA as an adjunct to diet and exercise to lower both low-density lipoprotein cholesterol (LDL-C) and glycated hemoglobin (A1C) levels in adults with primary hyperlipidemia and type 2 diabetes mellitus. It also describes the ADDvantage Program, an innovative program to help keep patients on their LDL-C and A1C medications by enabling them to save money on multiple prescriptions and providing valuable resources and tools to help get them to their LDL-C and A1C goals.
To view the Welchol® (colesevelam HCl) product information, please click here.
To view the full product bulletin, please click here or the image below.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
